Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection

References

• Dehesa-Violante M, Nuñez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res. 2007;38(6):606–611. doi:10.1016/j.arcmed.2007.03.001
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Cowie B. Global Hepatitis B Virus Elimination by 2030: China is Pivotal and Instructive. Oxford University Press US; 2021.
   Google Scholar
• Suk-Fong Lok A. Hepatitis B treatment: what we know now and what remains to be researched. Hepatol Commun. 2018;3:8–19.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206.
   PubMed Web of Science ®Google Scholar
• Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–195.
   PubMed Web of Science ®Google Scholar
• Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159:499–513.
   PubMed Web of Science ®Google Scholar
• Pefanis E, Wang J, Rothschild G, et al. RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell. 2015;161:774–789.
   PubMed Web of Science ®Google Scholar
• Alenquer M, Amorim MJ. Exosome biogenesis, regulation, and function in viral infection. Viruses. 2015;7(9):5066–5083. doi:10.3390/v7092862
   PubMed Web of Science ®Google Scholar
• Wang J, Cao D, Yang J. Exosomes in Hepatitis B virus transmission and related immune response. Tohoku J Exp Med. 2020;252(4):309–320. doi:10.1620/tjem.252.309
   PubMed Web of Science ®Google Scholar
• Jiao L, Qing L, Da-ming W, Xing-wang J. The association of mir-122 and mir-146a levels in serum exosomes with HBV DNA load in chronic hepatitis B patients. Chin Hepatol. 2020;25:1038.
   Google Scholar
• Wu W, Wu D, Yan W, et al. Exosomes with miR-574 transfer anti-HBV activity mediated by the interferon from macrophage to HBV-infected hepatocyte. J Infect Dis. 2020;223:4.
   Google Scholar
• Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer. 2016;15:1–14.
   PubMed Web of Science ®Google Scholar
• Graf J, Kretz M. From structure to function: route to understanding lncRNA mechanism. BioEssays. 2020;42:2000027.
   Web of Science ®Google Scholar
• Dragomir M, Chen B, Calin GA. Exosomal lncRNAs as new players in cell-to-cell communication. Transl Cancer Res. 2018;7:S243.
   PubMed Web of Science ®Google Scholar
• Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. British Medical Journal Publishing Group; 2007.
   Google Scholar
• Li X, Zhao J, Yuan Q, Xia N. Detection of HBV covalently closed circular DNA. Viruses. 2017;9:139.
   PubMed Web of Science ®Google Scholar
• Rekker K, Saare M, Roost AM, et al. Comparison of serum exosome isolation methods for microRNA profiling. Clin Biochem. 2014;47:135–138.
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras M, Shah SH, Tamayo A, et al. Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. Sci Rep. 2017;7:1–10.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Zou Y, et al. Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a–MET pathway. EBioMedicine. 2019;40:432–445.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Durantel D. New treatments to reach functional cure: virological approaches. Best Pract Res Clin Gastroenterol. 2017;31:329–336.
   PubMed Web of Science ®Google Scholar
• Yılmaz Susluer S, Kayabasi C, Ozmen Yelken B, et al. Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients. Bosnian J Basic Med Sci. 2018;18:150–161.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1–positive adults. J Acquir Immune Def Syndr. 2013;63:449–455.
   PubMed Web of Science ®Google Scholar
• Cathcart AL, Chan HL-Y, Bhardwaj N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic Hepatitis B infection. Antimicrob Agents Chemother. 2018;62:e01064–18.
   PubMed Web of Science ®Google Scholar
• Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Def Syndr. 2016;72:58–64.
   PubMed Web of Science ®Google Scholar
• Agarwal K, Fung S, Seto W, et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96. J Hepatol. 2017;66:S478.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos (t) ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578–1589.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Nakao M, Tsuji S, et al. Significance of switching of the nucleos (t) ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2020;92:329–338.
   PubMed Web of Science ®Google Scholar
• Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36:85–92.
   PubMed Web of Science ®Google Scholar
• Li S, Li S, Wu S, Chen L. Exosomes modulate the viral replication and host immune responses in HBV infection. Biomed Res Int. 2019;2019:1–9.
   Web of Science ®Google Scholar
• Li R, Fu X, Tang Y, et al. Expression profiles of the exosomal miRNAs in the chronic hepatitis B patients with persistently normal ALT. J Centr South Univ Med Sci. 2018;43:475–480.
   Google Scholar
• Yao Z, Qiao Y, Li X, et al. Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity. J Virol. 2018;92:e01578–18.
   PubMed Web of Science ®Google Scholar
• Li J, Liu K, Liu Y, et al. Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol. 2013;14:793–803.
   PubMed Web of Science ®Google Scholar
• Kouwaki T, Fukushima Y, Daito T, et al. Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection. Front Immunol. 2016;7:335.
   PubMed Web of Science ®Google Scholar
• Han M, Li Y, Wu W, et al. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Res. 2017;147:75–85.
   PubMed Web of Science ®Google Scholar
• Wu D, Wang P, Han M, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13:573–586.
   PubMed Web of Science ®Google Scholar
• Hermansson L, Yilmaz A, Price RW, et al. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS One. 2019;14:e0226276.
   PubMed Web of Science ®Google Scholar
• Feng J, Yang G, Liu Y, et al. LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer. Theranostics. 2019;9:5227.
   PubMed Web of Science ®Google Scholar
• Lu J, Xie F, Geng L, Shen W, Sui C, Yang J. Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. Tumor Biol. 2015;36:3231–3236.
   PubMed Web of Science ®Google Scholar
• Ren F, Ren J-H, Song C-L, et al. LncRNA HOTAIR modulates hepatitis B virus transcription and replication by enhancing SP1 transcription factor. Clin Sci. 2020;134:3007–3022.
   PubMed Web of Science ®Google Scholar
• Wu J, Niu Q, Yuan J, Xu X, Cao L. lncRNA‑CD160 decreases the immunity of CD8+ T cells through epigenetic mechanisms in hepatitis B virus infection. Oncol Lett. 2020;20:235–247.
   PubMed Web of Science ®Google Scholar